Along with climate change, the native forest replacement by exotic species, such as Eucalyptus globulus, is contributing to a highly fire-prone environment. Since E. globulus detains several post-fire regeneration strategies, sustainable practices are needed to manage eucalyptus stands. Thus, eucalyptus allelopathic potential can be used for weed control. Therefore, this study aimed at assessing the herbicidal potential of post-fire regenerated E. globulus leaves in Portulaca oleracea, and unraveling the main physiological processes disturbed by biocide application. For this, an aqueous extract prepared with fresh leaves (FLE; 617 g_{fresh weight}L^-1) and other with oven-dried leaves (DLE; 250 g_{dry weight}L^-1) were prepared and foliar-sprayed twice-a-week at different dilutions in 7-days-old purslane plants. As positive control, glyphosate was used. After five weeks, results revealed that DLE at the highest dose detained the greatest herbicidal activity against P. oleracea. To understand how DLE impacted weed physiology, several biochemical and redox-related parameters were evaluated in purslane plants treated with DLE highest dose. Results suggested an overproduction of hydrogen peroxide, causing severe oxidative damage in roots. Overall, this study showed that young E. globulus dried leaves had powerful herbicidal properties against P. oleracea and can represent a feasible approach for weed management, while reducing fire hazard.

Enzyme replacement therapy (ERT) improves the somatic manifestations in mucopolysaccharidoses (MPS))．However, because intravenously administered enzymes cannot cross the blood brain barrier (BBB), ERT is ineffective against the progressive neurodegeneration and resultant severe central nervous system (CNS) symptoms observed in patients with neuronopathic MPS. Attempts to surmount this problem have been made with intrathecal and intracerebroventricular ERT intend to achieve CNS effects, but the burdens on patients are inimical to long-term multiple administrations. However, after pabinafusp alfa, a human iduronate-2-sulfatase fused with a BBB-crossing anti-transferrin receptor antibody, showed both central and peripheral efficacy in mice model, subsequent clinical trials in a total of 62 patients with MPS-II (Hunter syndrome) in Japan and Brazil substantiated this dual efficacy and provided an acceptable safety profile. To date, pabinafusp alfa is the only approved intravenous ERT effective against both the somatic and CNS symptoms of patients with MPS-II. This article summarizes the hitherto obtained preclinical and clinical evidence associated with this drug, and discusses the preclinical, translational and clinical challenges of evaluating, ameliorating and preventing the neurodegeneration in patients with MPS-II.